Latest Breaking News On - Clin pract - Page 1 : comparemela.com

Astellas XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the European Commission (EC) has approved a.

United statesComunidad autonoma de catalunaAntonio alcarazAhsan arozullahEuropean unionDrug administrationEuropean association of urologyEuropean commissionDepartment of urologyAmerican society of clinical oncologyUniversity hospital clinic of barcelonaCommittee for medicinal products human useEuropean medicines agencyAstellas pharma incPrnewswire astellas pharma incHead of oncology development

Astellas XTANDItm (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas XTANDItm (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaUnited statesAhsan arozullahAntonio alcarazAmerican society of clinical oncologyEuropean medicines agencyPrnewswire astellas pharma incEuropean commissionCommittee for medicinal products human useHead of oncology developmentEuropean association of urologyUniversity hospital clinic of barcelonaDepartment of urologyDrug administrationEuropean unionAstellas pharma inc

Astellas XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaUnited statesAntonio alcarazAhsan arozullahDrug administrationUniversity hospital clinic of barcelonaEuropean medicines agencyEuropean unionCommittee for medicinal products human useAmerican society of clinical oncologyHead of oncology developmentEuropean association of urologyEuropean commissionDepartment of urologyPrnewswire astellas pharma incAstellas pharma inc

Pfizer and Astellas XTANDI® Approved by U S FDA in Earlier Prostate Cancer Treatment Setting

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the companies.

United statesChris boshoffNaoki okamuraAhsan arozullahCourtney buglerHead of oncology developmentAmerican urological association annual meetingAstellas pharma incDrug administrationOncology researchAmerican society of clinical oncologyCarolina urologic research centerPfizer incExchange commissionEuropean unionPrnewswire astellas pharma inc

European Medicines Agency Validates Type II Variation for Astellas XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

European Medicines Agency Validates Type II Variation for Astellas XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United statesNaoki okamuraAhsan arozullahDrug administrationMedivation incAmerican society of clinical oncologyEuropean unionAmerican urological association annual meeting onAstellas incHead of oncology developmentEuropean medicines agencyAstellas pharma incPrnewswire astellas pharma incSenior vice presidentOncology developmentUrological association annual meeting